Drug intelligence / Profile preview

Juxing Junzi Granules

Development stage: Preclinical
Administration: Oral

Overview

Juxing Junzi Granules (桔杏君子颗粒) is a Traditional Chinese Medicine (TCM) formula in granule form. It is currently being investigated for its efficacy and safety in treating convalescent patients of novel coronavirus pneumonia (COVID-19), particularly those presenting with Qi-Yin deficiency syndrome. Clinical studies have indicated that Juxing Junzi Granules can improve TCM syndrome scores and enhance the quality of life in these patients, demonstrating a high safety profile. Its therapeutic actions are rooted in TCM principles, aiming to benefit Qi, nourish Yin, strengthen the spleen, invigorate the lung, and resolve residual pathogenic factors.

Other names: 桔杏君子颗粒

Targets

SYK (Spleen Tyrosine Kinase)YY1 (Yin Yang 1 transcription factor)

Beyond the preview

Go deeper on Juxing Junzi Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Juxing Junzi Granules.

Explore the full profile